Umbilical cord blood-derived cellular products for cancer immunotherapy

Cytotherapy

Volumn 17, Issue 6, 2015, Pages 739-748

  Cany, Jeannette ^a   Dolstra, Harry ^a   Shah, Nina ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer immunotherapy; Cellular therapy; Cord blood; Expansion

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; CANCER VACCINE;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL SUBPOPULATION; CELL THERAPY; CLINICAL TRIAL (TOPIC); CULTURE TECHNIQUE; DENDRITIC CELL; DRUG EFFICACY; ENGRAFTMENT; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYMPTOM; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; UMBILICAL CORD BLOOD; CYTOLOGY; FETUS BLOOD; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; FETAL BLOOD; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84929043276     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.03.005     Document Type: Review

References (69)

1. Passweg J.R., Stern M., Koehl U., Uharek L., Tichelli A. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 2005, 35:637-643.
2. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
3. Cooley S., Weisdorf D.J., Guethlein L.A., Klein J.P., Wang T., Le C.T., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
4. Theilgaard-Monch K., Raaschou-Jensen K., Palm H., Schjødt K., Heilmann C., Vindeløv L., et al. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant 2001, 28:1073-1082.
5. Xing D., Ramsay A.G., Gribben J.G., Decker W.K., Burks J.K., Munsell M., et al. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. JImmunother 2010, 33:684-696.
6. Tanaka H., Kai S., Yamaguchi M., Misawa M., Fujimori Y., Yamamoto M., et al. Analysis of natural killer (NK) cell activity and adhesion molecules on NK cells from umbilical cord blood. Eur J Haematol 2003, 71:29-38.
7. Tomchuck S.L., Leung W.H., Dallas M.H. Enhanced Cytotoxic Function of Natural Killer and CD3(+)CD56(+) Cells in Cord Blood after Culture. Biol Blood Marrow Transplant 2015, 21:39-49.
8. Shah N., Martin-Antonio B., Yang H., Ku S., Lee D.A., Cooper L.J., et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013, 8:e76781.
9. Li Y., Schmidt-Wolf I.G., Wu Y.F., Huang S.L., Wei J., Fang J., et al. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res 2010, 30:3493-3499.
10. Satwani P., van de Ven C., Ayello J., Cairo D., Simpson L.L., Baxi L., et al. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy 2011, 13:730-738.
11. Spanholtz J., Tordoir M., Eissens D., Preijers F., van der Meer A., Joosten I., et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One 2010, 5:e9221.
12. Frias A.M., Porada C.D., Crapnell K.B., Cabral J.M., Zanjani E.D., Almeida-Porada G. Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion. Exp Hematol 2008, 36:61-68.
13. Kao I.T., Yao C.L., Kong Z.L., Wu M.L., Chuang T.L., Hwang S.M. Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34+ cells. Stem Cells Dev 2007, 16:1043-1051.
14. Spanholtz J., Preijers F., Tordoir M., Trilsbeek C., Paardekooper J., de Witte T., et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 2011, 6:e20740.
15. Cany J., van der Waart A.B., Tordoir M., Franssen G.M., Hangalapura B.N., de Vries J., et al. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS One 2013, 8:e64384.
16. Martin-Antonio B., Najjar A., Robinson S.N., Chew C., Li S., Yvon E., et al. Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ 2015, 22:96-107.
17. Hoshina T., Kida K., Ito M. Difference in response of NK cell activity in newborns and adult to IL-2, IL-12 and IL-15. Microbiol Immunol 1999, 43:161-166.
18. Nomura A., Takada H., Jin C.H., Tanaka T., Ohga S., Hara T. Functional analyses of cord blood natural killer cells and T cells: a distinctive interleukin-18 response. Exp Hematol 2001, 29:1169-1176.
19. Choi S.S., Chhabra V.S., Nguyen Q.H., Ank B.J., Stiehm E.R., Roberts R.L. Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture. Clin Diagn Lab Immunol 2004, 11:879-888.
20. Rutella S., Bonanno G., Marone M., De Ritis D., Mariotti A., Voso M.T., et al. Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after invitro exposure to IL-15. JImmunol 2003, 171:2977-2988.
21. McCullar V., Oostendorp R., Panoskaltsis-Mortari A., Yun G., Lutz C.T., Wagner J.E., et al. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol 2008, 36:598-608.
22. Perez S.A., Sotiropoulou P.A., Gkika D.G., Mahaira L.G., Niarchos D.K., Gritzapis A.D., et al. Anovel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 2003, 101:3444-3450.
23. Gaddy J., Broxmeyer H.E. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 1997, 180:132-142.
24. Chu Y., Hochberg J., Yahr A., Ayello J., van de Ven C., Barth M., et al. Targeting CD20+ Aggressive B-Cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA Modified Expanded Natural Killer Cells invitro and in NSG. Mice. Cancer Immunol Res 2014, 3:1-12.
25. Cho F.N., Chang T.H., Shu C.W., Ko M.C., Liao S.K., Wu K.H., et al. Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis. PLoS One 2014, 9:e109352.
26. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
27. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. JClin Oncol 2010, 28:955-959.
28. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. Aphase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
29. Mentlik James A., Cohen A.D., Campbell K.S. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013, 4:481.
30. Krieg S., Ullrich E. Novel immune modulators used in hematology: impact on NK cells. Front Immunol 2012, 3:388.
31. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
32. Palucka K., Banchereau J., Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
33. Hilkens C.M., Isaacs J.D. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?. Clin Exp Immunol 2013, 172:148-157.
34. Figdor C.G., de Vries I.J., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10:475-480.
35. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
36. Draube A., Klein-Gonzalez N., Mattheus S., Brillant C., Hellmich M., Engert A., et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011, 6:e18801.
37. Balan S., Kale V.P., Limaye L.S. Asimple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells. Transfusion 2009, 49:2109-2121.
38. Harada Y., Okada-Nakanishi Y., Ueda Y., Tsujitani S., Saito S., Fuji-Ogawa T., et al. Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells. Sci Rep 2011, 1:174.
39. Thordardottir S., Hangalapura B.N., Hutten T., Cossu M., Spanholtz J., Schaap N., et al. The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem Cells Dev 2014, 23:955-967.
40. Hutten T., Thordardottir S., Hobo W., Hübel J., van der Waart A.B., Cany J., et al. Exvivo generation of interstitial and Langerhans cell-like dendritic cell subset-based vaccines for hematological malignancies. JImmunother 2014, 37:267-277.
41. Banchereau J., Ueno H., Dhodapkar M., Connolly J., Finholt J.P., Klechevsky E., et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. JImmunother 2005, 28:505-516.
42. Florcken A., Kopp J., van Lessen A., Movassaghi K., Takvorian A., Jöhrens K., et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Hum Vaccin Immunother 2013, 9:1217-1227.
43. de Gruijl T.D., van den Eertwegh A.J., Pinedo H.M., Scheper R.J. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008, 57:1569-1577.
44. Fabre J.W. The allogeneic response and tumor immunity. Nat Med 2001, 7:649-652.
45. Tel J., Aarntzen E.H., Baba T., Schreibelt G., Schulte B.M., Benitez-Ribas D., et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013, 73:1063-1075.
46. Nierkens S., den Brok M.H., Garcia Z., Togher S., Wagenaars J., Wassink M., et al. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res 2011, 71:6428-6437.
47. Piccioli D., Tavarini S., Borgogni E., Steri V., Nuti S., Sammicheli C., et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 2007, 109:5371-5379.
48. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005, 23:275-306.
49. Yoneyama H., Matsuno K., Toda E., Nishiwaki T., Matsuo N., Nakano A., et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. JExp Med 2005, 202:425-435.
50. Kuwajima S., Sato T., Ishida K., Tada H., Tezuka H., Ohteki T. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 2006, 7:740-746.
51. Lou Y., Liu C., Kim G.J., Liu Y.J., Hwu P., Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. JImmunol 2007, 178:1534-1541.
52. Piccioli D., Sammicheli C., Tavarini S., Nuti S., Frigimelica E., Manetti A.G., et al. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 2009, 113:4232-4239.
53. Jounai K., Ikado K., Sugimura T., Ano Y., Braun J., Fujiwara D. Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells. PLoS One 2012, 7:e32588.
54. Boitano A.E., Wang J., Romeo R., Bouchez L.C., Parker A.E., Sutton S.E., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010, 329:1345-1348.
55. Hanley P.J., Cruz C.R., Shpall E.J., Bollard C.M. Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy 2010, 12:713-720.
56. Lee Y.S., Kim T.S., Kim D.K. Tlymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor. BMC Cancer 2011, 11:225.
57. Decker W.K., Shah N., Xing D., Lapushin R., Li S., Robinson S.N., et al. Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One 2012, 7:e51390.
58. Gattinoni L., Restifo N.P. Moving T memory stem cells to the clinic. Blood 2013, 121:567-568.
59. van der Waart A.B., van de Weem N.M., Maas F., Kramer C.S., Kester M.G., Falkenburg J.H., et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 2014, 124:3490-3500.
60. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NEngl J Med 2014, 371:1507-1517.
61. Serrano L.M., Pfeiffer T., Olivares S., Numbenjapon T., Bennitt J., Kim D., et al. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 2006, 107:2643-2652.
62. Klingemann H. Are natural killer cells superior CAR drivers?. Oncoimmunology 2014, 3:e28147.
63. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. JCancer 2011, 2:363-368.
64. Introna M., Franceschetti M., Ciocca A., Borleri G., Conti E., Golay J., et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006, 38:621-627.
65. Liu H., Song J., Yang Z., Zhang X. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med 2013, 6:953-956.
66. Wang S., Zhang H., Liu C., Jiao X., Liu D., DU W., et al. Human leukocyte antigen-haploidentical donor-derived cytokine-induced killer cells are safe and prolong the survival of patients with advanced non-small cell lung cancer. Oncol Lett 2014, 8:2727-2733.
67. Deniger D.C., Moyes J.S., Cooper L.J. Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol 2014, 5:636.
68. Deniger D.C., Maiti S.N., Mi T., Switzer K.C., Ramachandran V., Hurton L.V., et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 2014, 20:5708-5719.
69. Lund T.C., Boitano A.E., Delaney C.S., Shpall E.J., Wagner J.E. Advances in umbilical cord blood manipulation-from niche to bedside. Nat Rev Clin Oncol 2015, 12:163-174.